During the 2024 European Congress on Obesity, a variety of experts presented research on combating the issue. Here's a summary of the main discoveries.
Screen use during meals linked to childhood obesity
A study involving 735 primary schoolchildren aged six to ten revealed that those who frequently used smartphones or other screens during meals were 15% more likely to be overweight. Dr Ana Duarte Mel, the lead researcher from the University of Minho, highlighted that screen distractions during meals hinder children's ability to recognise when they're full, potentially leading to overeating and obesity. She emphasised the importance of family mealtime without screens to address this growing concern.
Britons still reluctant towards insect foods
Research suggests that while insect-based foods are consumed worldwide, they still lack appeal in the UK. A study conducted an online survey of 603 UK adults between 2019 and 2020, revealing that only 13% of respondents were open to regularly consuming insects, whereas 47% expressed unwillingness. Dr Lauren McGale from Edge Hill University, the lead author, emphasised that insects could address the dual challenge of obesity and undernutrition, being a potentially rich source of protein and micro-nutrients.
Financial incentives can help
A year-long study found that text messages and cash incentives helped men with obesity lose weight. In a group of 585 men, those receiving texts with financial incentives lost 4.8% of body weight, compared to 2.7% in the group without incentives. Researchers suggest this strategy could be adopted by the NHS.
New drug which could be more effective than Ozempic
A new weight-loss injection called Retatrutide, administered weekly, has shown promising results in a phase 2 clinical trial. Participants, numbering 338 and living with obesity, lost nearly a quarter of their body weight over 48 weeks. Unlike existing rivals like Ozempic and Wegovy, Retatrutide not only suppresses appetite but also aids fat burning. Researchers anticipate its potential availability on the NHS by 2026, pending further clinical trials.
